Ipca Laboratories Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3q5ou77a2zo5z5j9k71yl185.pdf

Key Takeaways


Guidance Revision & The Unichem Question

A.K. Jain: "Unichem guidelines, I'm not revising right now. Let's see for some more quarters how it performs and we are working hard to deliver more growth, but let us see on ground and thereafter, we'll revise the guidelines."

Unichem: The Integration Payoff

A.K. Jain: "Maybe around 15%, 16%, 17% kind of growth is possible, but currently looking at portfolio and other things."

Margin Walk & Cost Structure

A.K. Jain: "In fact, before these dollar depreciation started, we have almost every dollar loan prepaid every dollar loan. We don't have those kind of debt in books."

India Business & Field Force

A.K. Jain: "I think there are no such renegotiations of the prices where the prices are to be reduced, no. Rather we are increasing the prices everywhere because your costs are also moving up."

Biotech: The Long-Dated Option

A.K. Jain: "Most of the products are -- known titer values are practically double or more of the current known in the market side."

Lyka Labs & Other Portfolio Items


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growth14–16% for FY27, raised from 12–13%FY27
Consolidated EBITDA margin~23%, raised from ~22%FY27
India business growth12–13%FY27
Institutional business₹260–300 cr, single-digit growthFY27
Unichem growth and EBITDA margin10% growth, 13% EBITDA margin, unchangedFY27, under review
U.S. growth~15–17% possible on current portfolioFY27
U.S. launches~7–8 combined Ipca-Unichem per yearAnnual run-rate
Capex₹700–800 crFY27
Term loan repayment~₹70 cr year-end balance repaidFY28
Medium-term standalone margin~26% to ~30%2–3 years
Medium-term consolidated margin~25%2–3 years
Biotech revenue startFY29–FY30FY29–FY30
Biotech clinical trials startNext financial yearFY28
FY28 guidanceTo be given at Q4Q4 FY27

Key Metrics

MetricQ1 FY27
Consolidated revenue₹2,788 cr, +21% YoY from ₹2,309 cr
Consolidated EBITDA margin22.88%, up from 18.39% YoY, an improvement of ~4.49 ppt
Consolidated EBITDA₹638 cr, +50% YoY from ₹425 cr
Standalone EBITDA margin26%, up from 23.82% YoY
Standalone EBITDA₹557 cr, +34% YoY from ₹416 cr
Domestic formulation revenue₹1,082 cr, +13% YoY from ₹961 cr
Export revenue₹603 cr, +34% YoY from ₹450 cr
API revenue₹424 cr, +30% YoY from ₹362 cr
FY27 revenue growth guidance14% to 16%, revised upward from 12% to 13%
FY27 consolidated EBITDA margin guidance~23%, revised upward from ~22%
Domestic formulation volume growth~5%
Domestic formulation price growth~4.5% to 5%
Domestic formulation new product launch contribution~2%
IQVIA market share~2.08%, up from 2.07% in March 2026
Chronic segment growth~17.2%, vs IPM chronic growth of ~15.2%
Acute segment growth~8.9%, vs IPM growth of 4.5%
Institutional generic revenue₹111.75 cr, +107% YoY from ₹58 cr; includes ~₹40 cr of March shipment shifted to April
Generic business excluding tender₹340 cr, +27% YoY from ₹268 cr
Promotional branded ROW revenue₹143 cr, +16% YoY from ₹124 cr
EU business revenue₹137 cr, up from ₹33 cr YoY
U.S. shipments growth~8% YoY
Unichem U.S. business growth~27% YoY
Unichem Brazil growth~52% YoY
Unichem API revenue~₹58 cr, +73% YoY from ₹33–34 cr
Acacia (ROW) revenue₹17 cr, nearly double from ₹8 cr YoY
Material cost to sales~25% of sales; savings contributed only 0.14% to EBITDA margin improvement
Personnel cost to sales change-1.41% YoY
Manufacturing cost to sales change-0.91% YoY
Rupee depreciation contribution to revenue growth5% of the 21% overall growth; dollar up ~11% YoY
India field force~7,000 medical reps; plan to add ~200 mid-year
Capex guidance FY27₹700–800 cr
Long-term debt₹193 cr; zero working capital debt; year-end term loan balance expected ~₹70 cr
Biotech pipeline7 candidates; 2 in engineering batches; ~₹100 cr additional biotech investment this year
U.S. launches per year (Ipca + Unichem)7 to 8 combined; 3–4 each
U.S. growth expectation~15% to 17% possible
Standalone EBITDA margin long-term potential~30%, up from current ~26%
Consolidated EBITDA margin in 2–3 years~25%